Literature DB >> 29565706

LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway.

Fei Liu1, Yong Tai1, Jiqing Ma1.   

Abstract

The long non-coding RNA nuclear paraspeckle assembly transcript 1 (NEAT1) was reported to be upregulated and be involved in oncogenic growth and drug resistance in nasopharyngeal carcinoma (NPC). However, the exact roles of NEAT1 and its underlying mechanisms in the drug resistance of NPC remain largely unclear. In this study, the expressions of NEAT1, let-72-5p and Rsf-1 mRNA were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of NEAT1 and let-72-5p on cell proliferation and cisplatin resistance of NPC cells were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and 5-ethynyl-20-deoxyuridine (EdU) assay. Western blot analysis was performed to detect the protein levels of Rsf-1, Ras, p-Raf1, Raf1, p-MEK1, MEK1, p-ERK1/2 and ERK1/2. Xenograft tumor assay was done to elucidate the role of NEAT1 involved in NPC tumor growth in vivo. We found that NEAT1 was upregulated and let-7a-5p was downregulated in NPC tissues, as well as NPC cell lines. Inhibition of NEAT1 markedly repressed the cisplatin resistance of NPC cells. NEAT1 was demonstrated to interact with let-7a-5p. Besides, a negative correlation between NEAT1 and let-7a-5p expression was observed in NPC tissues. Rsf-1 was confirmed as a target of let-7a-5p. NEAT1 remarkably reversed the inhibitory effect of let-7q-5p on the cisplatin resistance of NPC cells in vitro. Additionally, NEAT1 knockdown inhibited the Ras-MAPK pathway in NPC cells. NEAT1 knockdown suppressed tumor growth in the presence of cisplatin in vivo. Overall, these findings suggest that NEAT1/let-7a-5p axis regulates the cisplatin resistance in NPC by targeting Rsf-1 and modulating the Ras-MAPK signaling pathway.

Entities:  

Keywords:  Ras-Mapk pathway; Rsf-1; cisplatin; let-7a-5p; long non-coding RNA; nasopharyngeal carcinoma; nuclear paraspeckle assembly transcript 1

Mesh:

Substances:

Year:  2018        PMID: 29565706      PMCID: PMC5927658          DOI: 10.1080/15384047.2018.1450119

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  34 in total

1.  Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a.

Authors:  Xigang Hu; Huijuan Jiang; Xiaojun Jiang
Journal:  Cancer Biol Ther       Date:  2017-04-12       Impact factor: 4.742

2.  Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma.

Authors:  Feng Pan; Zhihua Ruan; Jianjun Li; Xueli Pang; Yanling Zhang; Lan Zou; Houjie Liang
Journal:  Med Oncol       Date:  2015-10-15       Impact factor: 3.064

3.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

4.  RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.

Authors:  Gorjan Hrustanovic; Trever G Bivona
Journal:  Mol Cell Oncol       Date:  2015-10-29

5.  RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.

Authors:  Xuesong Zhao; Tatyana Ponomaryov; Kimberly J Ornell; Pengcheng Zhou; Sukriti K Dabral; Ekaterina Pak; Wei Li; Scott X Atwood; Ramon J Whitson; Anne Lynn S Chang; Jiang Li; Anthony E Oro; Jennifer A Chan; Joseph F Kelleher; Rosalind A Segal
Journal:  Cancer Res       Date:  2015-06-30       Impact factor: 12.701

6.  MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation.

Authors:  Cheng-Chia Yu; Yi-Wei Chen; Guang-Yuh Chiou; Lo-Lin Tsai; Pin-I Huang; Charn-Yung Chang; Ling-Ming Tseng; Shih-Hwa Chiou; Sang-Hue Yen; Ming-Yung Chou; Pen-Yuan Chu; Wen-Liang Lo
Journal:  Oral Oncol       Date:  2011-02-02       Impact factor: 5.337

7.  LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis.

Authors:  Qiaosu Wang; Wenjing Zhang; Shaojuan Hao
Journal:  Cell Cycle       Date:  2017-03-30       Impact factor: 4.534

8.  Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer.

Authors:  Shuli Liu; Qianze Dong; Enhua Wang
Journal:  Tumour Biol       Date:  2012-04-20

Review 9.  Long non-coding RNAs: modulators of nuclear structure and function.

Authors:  Jan H Bergmann; David L Spector
Journal:  Curr Opin Cell Biol       Date:  2013-09-20       Impact factor: 8.382

10.  Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells.

Authors:  Chongwen Xu; Xin Sun; Sida Qin; Huangzhen Wang; Zhiwei Zheng; Shaohua Xu; Gang Luo; Peng Liu; Jian Liu; Ning Du; Yunfeng Zhang; Dapeng Liu; Hong Ren
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more
  33 in total

Review 1.  Long non-coding RNAs in nasopharyngeal carcinoma: biological functions and clinical applications.

Authors:  Yao Tang; Xiusheng He
Journal:  Mol Cell Biochem       Date:  2021-05-17       Impact factor: 3.396

2.  The role of NEAT1 lncRNA in squamous cell carcinoma of the head and neck is still difficult to define.

Authors:  Joanna Kozłowska; Kinga Kozioł; Maciej Stasiak; Justyna Obacz; Kacper Guglas; Paulina Poter; Andrzej Mackiewicz; Tomasz Kolenda
Journal:  Contemp Oncol (Pozn)       Date:  2020-07-03

3.  NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis.

Authors:  Mingzhe Zhu; Lei Yang; Xin Wang
Journal:  Cancer Manag Res       Date:  2020-08-14       Impact factor: 3.989

4.  Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.

Authors:  Xinfang Yu; Ruike Wang; Yangnan Zhang; Li Zhou; Wei Wang; Haidan Liu; Wei Li
Journal:  Oncogene       Date:  2019-08-21       Impact factor: 9.867

5.  Silencing long non-coding RNA NEAT1 attenuates rheumatoid arthritis via the MAPK/ERK signalling pathway by downregulating microRNA-129 and microRNA-204.

Authors:  Jie Chen; Xiao Luo; Mao Liu; Lihui Peng; Zixia Zhao; Chengsong He; Yue He
Journal:  RNA Biol       Date:  2021-01-20       Impact factor: 4.652

6.  Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer.

Authors:  Wu Yong; Deng Yu; Zhu Jun; Duan Yachen; Weng Weiwei; Xu Midie; Ju Xingzhu; Wu Xiaohua
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

7.  Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.

Authors:  Vivian Yvonne Shin; Jiawei Chen; Isabella Wai-Yin Cheuk; Man-Ting Siu; Chi-Wang Ho; Xian Wang; Hongchuan Jin; Ava Kwong
Journal:  Cell Death Dis       Date:  2019-03-20       Impact factor: 8.469

Review 8.  RSF1 in cancer: interactions and functions.

Authors:  Guiyang Cai; Qing Yang; Wei Sun
Journal:  Cancer Cell Int       Date:  2021-06-19       Impact factor: 5.722

Review 9.  Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer.

Authors:  Alma D Campos-Parra; Eduardo López-Urrutia; Luz Tonantzin Orozco Moreno; César López-Camarillo; Thuluz Meza-Menchaca; Gabriela Figueroa González; Lilia P Bustamante Montes; Carlos Pérez-Plasencia
Journal:  Int J Mol Sci       Date:  2018-09-11       Impact factor: 5.923

Review 10.  Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.

Authors:  Peixin Dong; Ying Xiong; Junming Yue; Sharon J B Hanley; Noriko Kobayashi; Yukiharu Todo; Hidemichi Watari
Journal:  Front Genet       Date:  2018-10-15       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.